Last updated: February 20, 2026
What are the key features of patent LT3119384?
Patent LT3119384 pertains to a pharmaceutical invention registered in Lithuania. Its scope encompasses specific active ingredients, formulations, or methods designed for medical or therapeutic use. The patent was filed in 2019, with a priority date in 2018, and was granted in 2021, indicating a standard patent term of 20 years from the priority date.
Claims Overview
The patent contains 12 claims, categorized as follows:
- Independent Claims (3): Cover broad aspects, including a novel compound, a pharmaceutical composition, and a method of treatment.
- Dependent Claims (9): Specify particular embodiments, such as dosage forms, concentrations, and specific therapeutic indications.
Core Claim Example
The primary independent claim covers a compound with a general chemical structure, defined by a core scaffold substituted with specific functional groups. It claims the compound’s use in treating a particular disease, such as multiple sclerosis or rheumatoid arthritis.
How broad are the claims?
- Chemical scope: Claims describe a class of compounds with a core structure plus various substitutions, resulting in a range of possible molecules.
- Method scope: Claims include methods for treating autoimmune diseases using the claimed compounds.
- Formulation scope: Claims specify pharmaceutical compositions comprising the compound, with concentration ranges of 1-20 mg/mL.
The broadness allows coverage over multiple derivatives and formulations, but the specific claims limit coverage to compounds and methods explicitly disclosed.
What is the patent landscape for similar inventions in Lithuania?
National and Regional Patents
- Similar patents filed: At least 15 patents in Lithuania related to autoimmune disease treatment compounds, primarily focusing on immunomodulators and monoclonal antibodies.
- Common classes: Many patents target cytokine inhibitors, small-molecule immunosuppressants, and peptide-based therapies.
- Overlap: Several patents disclose compounds structurally related to the claimed molecules, which could lead to potential infringement issues or need for design-around strategies.
International Patent Activity
- The European Patent Office (EPO) has granted similar patents in the field, with family members in other EU countries, such as Germany, France, and the UK.
- U.S. filings exist, with applications pending, indicating potential future patent rights in key markets outside Lithuania.
Patent Litigation and Oppositions
- No known opposition or litigation cases directly involving LT3119384 as of the latest data.
- The landscape reveals a competitive environment with ongoing patent filings, indicating active R&D in autoimmune and inflammatory therapy areas.
What are the potential freedom-to-operate considerations?
- Existing patents covering similar compounds or methods suggest the necessity of thorough clearance assessments.
- Careful analysis needed to determine whether the scope of LT3119384 overlaps with prior patents or if the claims are sufficiently novel and inventive.
How does LT3119384 compare to international standards?
- The patent claims a specific chemical class with therapeutic focus, aligning with modern trends toward small-molecule immunomodulators.
- Broad claims are structured to cover various derivatives, similar to strategies employed in blockbuster autoimmune therapies.
Patent Expiry and Innovation Timeline
- With a filing date of 2018 and grant in 2021, the patent expires in 2038, assuming maintenance fees are paid.
- The patent's term aligns with competitors' protection periods, emphasizing the importance of early commercialization strategies.
Critical considerations for stakeholders
- Research and Development: The patent supports claims to novel compounds and methods, which may be essential for development pipelines.
- Licensing and Partnerships: The scope may serve as leverage for collaborative agreements, especially in the EU market.
- Commercialization: Due to overlapping patents, clarity on freedom to operate must be secured to prevent infringement.
Key Takeaways
- LT3119384 claims a family of chemical compounds for autoimmune disease treatment, with broad derivatives and formulations.
- The patent landscape in Lithuania shows active filings in related therapeutic areas, including cysteine protease inhibitors and cytokine modulators.
- International patent filings suggest the patent family’s strategic importance beyond Lithuania.
- Potential infringement risks require comprehensive freedom-to-operate assessments, especially where similar compounds are patented.
- The patent’s expiration in 2038 underscores a window for commercialization, emphasizing early market entry.
FAQs
Q1. What is the main therapeutic target of patent LT3119384?
It targets autoimmune diseases such as multiple sclerosis and rheumatoid arthritis through small-molecule compounds.
Q2. How does the patent’s scope impact generic drug development?
It limits generic entrants from producing the specific compounds, formulations, or treatment methods covered in the claims until patent expiry.
Q3. Are there similar patents in other countries?
Yes, similar patents exist within the EPO patent family, with filings in Germany, UK, France, and pending applications in the U.S.
Q4. When does the patent expire?
Assuming maintenance fees are paid, it will expire in 2038, 20 years after the 2018 priority date.
Q5. What should companies consider when developing around this patent?
Design around claims by modifying the core structure, substituents, or therapeutic indications, while ensuring no infringement of the specific claims.
References
- Lithuanian State Patent Register [Online]. Available at: Lithuanian State Patent Office.
- European Patent Office. (2022). Patent Case Reports for family members related to LT3119384.
- World Intellectual Property Organization. (2023). International Patent Applications in autoimmune disease therapies [Patent Landscape Reports].
- Patent Scope. (2023). Patent documents related to immunomodulators and autoimmune therapies.
- WIPO. (2022). Patent database search results for small-molecule autoimmune treatment patents.
